Beta Bionics (BBNX) Common Equity (2023 - 2026)

Beta Bionics has disclosed Common Equity across 4 years of filings, most recently posting $271.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $271.2 million, down 13.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $271.2 million (down 13.55% YoY), and the FY2025 annual result was $287.6 million, up 217.22% from the prior year.
• Common Equity came in at $271.2 million for Q1 2026 at Beta Bionics, down from $287.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $313.8 million in Q1 2025 to a low of -$245.4 million in Q4 2024.
• The 4-year median for Common Equity is $34.1 million (2023), against an average of $35.6 million.
• Across the five-year window, Common Equity retreated 20.8% in 2024 and jumped 246.39% in 2025, its largest moves.
• Beta Bionics' Common Equity stood at -$203.1 million in 2023, then slipped by 20.8% to -$245.4 million in 2024, then surged by 217.22% to $287.6 million in 2025, then dropped by 5.69% to $271.2 million in 2026.
• The last three Common Equity figures came in at $271.2 million (Q1 2026), $287.6 million (Q4 2025), and $294.8 million (Q3 2025), per Business Quant data.